Nasopharyngeal Carcinoma

Oncology
6
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
1
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

CT
3 programs
2
1
Gemcitabine/CisplatinPhase 31 trial
TQB2450Phase 21 trial
TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride InjectionPhase 21 trial
Active Trials
NCT04895345CompletedEst. Apr 2024
NCT05563480UnknownEst. May 2024
NCT03601975UnknownEst. Jul 2021
MediLink Therapeutics
MediLink TherapeuticsChina - Suzhou
1 program
1
YL201Phase 31 trial
Active Trials
NCT06629597RecruitingEst. Dec 2028
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1706Phase 2/31 trial
Active Trials
NCT05576272UnknownEst. Dec 2024
M&
Merck & Co.RAHWAY, NJ
1 program
1
Bintrafusp AlfaPhase 21 trial
Active Trials
NCT04396886CompletedEst. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
MediLink TherapeuticsYL201
Chia Tai TianQing Pharmaceutical GroupGemcitabine/Cisplatin
Qilu PharmaceuticalQL1706
Chia Tai TianQing Pharmaceutical GroupTQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
Chia Tai TianQing Pharmaceutical GroupTQB2450
Merck & Co.Bintrafusp Alfa

Clinical Trials (6)

NCT06629597MediLink TherapeuticsYL201

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Start: Dec 2024Est. completion: Dec 2028
Phase 3Recruiting
NCT03601975Chia Tai TianQing Pharmaceutical GroupGemcitabine/Cisplatin

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

Start: Aug 2018Est. completion: Jul 2021
Phase 3Unknown
NCT05576272Qilu PharmaceuticalQL1706

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Start: May 2022Est. completion: Dec 2024
Phase 2/3Unknown
NCT05563480Chia Tai TianQing Pharmaceutical GroupTQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Start: Oct 2022Est. completion: May 2024
Phase 2Unknown
NCT04895345Chia Tai TianQing Pharmaceutical GroupTQB2450

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Start: Jun 2021Est. completion: Apr 2024
Phase 2Completed
NCT04396886Merck & Co.Bintrafusp Alfa

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Start: Feb 2020Est. completion: Jul 2023
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
15m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
15m ago

Office Administrator

SystImmune
15m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
25m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
29m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
29m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)